





Whipping GPCRs into shape for structure determination

Chris Tate



G protein-coupled receptors (GPCRs) are found throughout the human body and are targeted by 34% of FDA approved small molecule drugs

- Nervous system
- Visual system
- Cardiovascular system
- Respiratory system
- Immune regulation
- Digestion and gut function
- Kidney function
- Liver metabolism
- Musculoskeletal system
- Puberty and reproduction
- Wound healing



OXYCONTIN[®]
(OXYCODONE HCl CONTROLLED-RELEASE) TABLETS

ABILIFY[®]
ARIPIPRAZOLE

ZYPREXA[®]
IntraMuscular
Clonazepam for Injection

SPIRIVA[®]
(tiotropium)

Suboxone[®]
(buprenorphine HCl/naloxone HCl dihydrate) © Watson Labs

GEODON[®]
(ziprasidone HCl) Capsules

Byetta[®]
exenatide injection

Sensipar[®]
(cinacalcet) Tablets

Plavix[®]
Clopidogrel 75 mg

ADVAIR[®]
salmeterol xolinate / fluticasone propionate

ONCE-A-DAY
SINGULAIR[®]
(MONTelukAST SODIUM)

Seroquel[®]
quetiapine


Diovan[®]
valsartan capsules

Ventolin HFA[®]
(albuterol sulfate)
inhalation aerosol

Detrol[®] LA
tolterodine tartrate
extended release capsules


Benicar[®] TABLETS
(olmesartan medoxomil)

Signal transduction by GPCRs




GPCRs have a rich pharmacology and are highly dynamic

- the efficacy of synthetic ligands varies



- agonist binding increases the probability of G protein coupling
- binding of a G protein increases agonist affinity
- agonist binding to some receptors is inhibited by Na^+



R : receptor in an inactive conformation

R^* : receptor in an active conformation

Ag : agonist

G : G protein (or mimetic)

Ant : antagonist

Conformational changes upon GPCR
activation: coupling of mini-G_s to A_{2A}R


Inactive state

- agonist binding
- contraction of ligand binding pocket (LBP)
- conformational change
- opening of cleft on cytoplasmic face


Active intermediate

- G protein binding

Active state



Engineering GPCRs has been essential for the success of structure determination



Congreve et al (2020) Cell **181**, 81-91

Factors to consider in structure determination

(1) Improve potential crystal contacts

- Remove flexible regions and post-translational modifications
- Fuse to soluble proteins (T4L, BRIL etc)
- Use binding partners (F_{ab} , nanobody)

(2) Reduce conformational heterogeneity

- Add ligands (inverse agonist, agonist)
- Bind antibodies (F_{ab} , nanobody)
- Add point mutations

(3) Increasing thermostability



- Add ligands (inverse agonist, agonist)
- Bind antibodies (F_{ab} , nanobody)
- Add point mutations

Expression systems for GPCRs


| | Complexity of the expression system | Ratio functional: non- functional receptor | Potential expression level of functional receptor |
|------------------------------------|--|---|--|
| • Cell free systems | + | -/+ | ++ |
| • <i>Escherichia coli</i> | + | -/+ | ++ |
| • Yeast species | ++ | + | ++ |
| • Baculovirus | +++ | ++ | ++++ |
| • Mammalian cells | | | |
| • Transient transfection | ++++ | ++ | +++ |
| • Stable cell lines : Constitutive | ++++ | ++++ | +++ |
| : Inducible | ++++ | ++++ | ++++ |
| • Viral systems : BacMam | ++++ | ++++ | ++++ |
| : Lentivirus | ++++ | ++++ | ++++ |

Expression is receptor-dependent and user-dependent!

Discrimination of misfolded GPCRs by a differential detergent solubility or confocal fluorescent microscopy



Membrane protein folding is complex and poorly understood



Engelman et al. (2003)
FEBS Lett. 555, 122-125


- Years have been spent trying to get mammalian membrane proteins to express in bacteria or yeast
- Use baculovirus or mammalian systems and save a lot of grief

2005: Making GPCRs behave




Protein engineering of the β_1 -adrenoceptor (β_1 AR) for X-ray crystallography

Wild type turkey β_1 AR



Potential problems from sequence analysis

- Large potentially flexible regions (N-term, C-term, ICL3)
- Palmitoylation site
- N-glycosylation site
- Multiple phosphorylation sites



Disorder prediction (PrDOS)



Tony Warne



Attempts to engineer β_1 AR for X-ray crystallography: 7 years in purgatory

β_1 AR constructs

β_6 : $\Delta 3$ -32 (N-term)

β_{36} : $\Delta 3$ -32 (N-term)
 $\Delta 368$ -483 (C-term)
 $\Delta 244$ -271,277,278 (ICL3)
C358A


Purified 2.5 mg β_6 or β_{36}
per L of insect cells




No crystals!

The receptor was too unstable in short-chain detergents

The dynamics of short chain detergents explains why they are so denaturing



A_{2A}R in DDM



A_{2A}R in OG

Conformational thermostabilisation:

Stabilisation of membrane proteins preferentially in a particular state to allow the use of short-chain detergents in crystallography



Magnani *et al* (2018) *Nature Protocols* 8, 1544-1571

Construction of Ala/Leu scanning
mutants throughout the MP
Steps 1-11



Expression of the MP mutants by
transient transfection in HEK293 cells
Steps 12-17



Thermostability assay of Ala-scan mutants
Steps 18-27



Accurate apparent T_m determination of a
subset of single mutants
Steps 28-34







Combination of thermostabilising mutations
into an optimally thermostable MP
Steps 35-40



Determination of the thermostability in
short-chain detergents suitable for
crystallisation and structure determination




Structure determination




Conformational thermostabilisation of β_1 AR


Constructing β AR-m23




β AR-m23 was stable in short chain detergents




β AR-m23



Agonist binding




Antagonist binding




The receptor was now stable in short chain detergents and it crystallised in OTG

Engineered construct of β_1 AR that crystallised:
thermostability has allowed crystallisation with any ligand
(23 structures determined to date)



Understanding the molecular pharmacology of the β_1 -adrenoceptor (β_1 AR) through X-ray crystallography



- Inactive state
- Active state + arrestin
- ▲ Active state + G protein

Full agonist




Partial agonist

Inverse agonist


Increasing efficacy

| | Inactive state 1 | Inactive state 2 | Active state |
|------------------------|------------------|------------------|--------------|
| Formoterol | | | B |
| Carmoterol | | B | |
| Isoprenaline | | | |
| Dobutamine | | | |
| Salbutamol | | | |
| Cyanopindolol | | | |
| Iodocyanopindolol | | | |
| Carazolol | | | |
| Carvedilol | B | | |
| Bucindolol | B | | |
| 7-Methyl cyanopindolol | | | |

B: arrestin biased signalling



Gene fusion is another strategy to obtain structures of GPCRs




Insert the sequence of:
T4 lysozyme
Cytochrome B562 or BRIL
(now many others as well)

- The position of fusion junction points is critical
- Start with known fusion points and test neighbours
- One amino acid difference in position can affect thermostability and also diffraction quality of crystals
- Good crystals can only be grown in lipid cubic phase
- High affinity ligands essential to stabilise the receptor

See GPCRdb for engineering tools

Three strategies to determine the structure of the adenosine A_{2A} receptor



A: Hino et al (2012) Nature **482**, 237
B: Xu et al (2011) Science **332**, 322
C: Doré et al (2011) Structure **19**, 1283
D: Lebon et al (2011) Nature **474**, 521


Engineering a minimal G protein suitable for crystallising GPCR-G protein complexes





Structure of the agonist-bound β_2 -adrenoceptor in complex with a heterotrimeric G protein

Rasmussen *et al.* (2011) *Nature* **477**, 549-555

- 97% of atomic interactions between G_s and β_2 AR are mediated by $G\alpha$
- 70% of the surface area between $G\alpha$ and β_2 AR is mediated by the $\alpha 5$ helix



Agonist-shift assays for the development of mini-G_s :
Assay for the desired trait *i.e.* G protein-coupling




$\beta_1\text{AR-WT}$: truncated wild-type receptor
 $\beta_1\text{AR-84}$: thermostabilised receptor in
the antagonist conformation

G_s : heterotrimeric G protein $G\alpha\beta\gamma$
 $G_s\text{-Nb35}$: heterotrimeric G protein $G\alpha\beta\gamma$



stabilised by nanobody Nb35

Nb80 : G protein mimetic


The isolated GTPase domain of $G\alpha$ was very unstable, poorly expressed and could not be purified to homogeneity, but it did couple to β_1AR



Ni²⁺-NTA 'purified'
GTPase domain
~200 $\mu\text{g/L}$ *E. coli*




GTPase domains are highly conserved:
Alignment between the GTPase domain of $G\alpha$ and the small GTPase Arl2




Mini-G_s is the stabilised GTPase domain of G α_s

- 28 kDa protein expressed at 100 mg/L in *E. coli* (a)
- Contains 8 mutations and 3 deletions
- Mutations decouple nucleotide exchange from activation of mini-G_s and GPCR binding
- Gives the same shift in agonist affinity as the G_s heterotrimer either in detergent or membranes (b)
- Forms a stable complex with many G_s-coupled GPCRs in the presence of agonist
- The complex of the adenosine A_{2A} receptor with mini-G_s is more stable in octylglucoside than the equivalent complex formed by the G_s heterotrimer and Nb35 (c)
- Suitable for crystallisation by vapour diffusion

Carpenter & Tate (2016) Protein Eng. Design Sel. **29**, 583-594



Overall structure of the A_{2A}R–mini-G_s complex compared to the β₂AR–G_s complex





Strategies for structure determination by cryo-EM




MRC Laboratory
of Molecular
Biology

A particularly nasty beast: the glycoprotein hormone receptor TSHR





- Extracellular leucine-rich repeat domain
- C-peptide sometimes present in hinge region connecting ECD and TMD
- ~Six N-linked glycosylation sites
- Five disulphide bonds

Cryo-EM allows the use of very mild detergents that tend to be large and are incompatible with crystallisation of GPCRs





Assessing receptor quality and quantity: Fluorescence size-exclusion chromatography





FSEC is used to determine the ability of detergents to solubilise the receptor and to maintain it in a monodisperse state

Transient transfection





- Large amounts of intracellular aggregates
- No defined receptor peak in any detergent on FSEC
- Transfected cells are unhealthy

Lentiviral transduction




- Monodisperse peak
- Both DDM and LMNG are suitable
- Little intracellular aggregation
- Healthy cells on TSHR expression


Improving solubilisation and stability: Increasing NaCl concentration



FSEC can also be used to detect the formation of G protein complexes



Structure of 5HT_{1B}R coupled to heterotrimeric G_o





Differences in engineering strategy between cryo-EM and X-ray approaches

| | X-ray | cryo-EM |
|--|-------|---------|
| Remove flexible regions? | Yes | No |
| Remove post-translational modification? | Yes | No |
| Add hydrophilic regions for crystal contacts? | Yes | No |
| Can thermostability of the receptor be a problem? | Yes | No |
| Can protein dynamics be a problem? | Yes | No/Yes |
| Can I use any detergent? | No | Yes |
| Do I need to worry about the size of the receptor? | No | Yes* |
| Is the shape of a complex problematic? | Yes | No |
| Do I have to worry about my complex dissociating? | Yes | Yes |

The last 'wet' hurdle: cryo-EM grid preparation (cf crystal screening)


- Dissociation of complexes or aggregate of protein at the air-water interface
- Preferred orientation on an EM grid prevents structure determination

Preferred orientation of the β_1 AR-arrestin complex




- Add detergents before blotting to decrease surface tension
- Try different grids e.g. gold vs copper
- Try different supports e.g. unsupported, carbon, graphene
- Try different modifications to supports e.g. glow discharging in different solvents
- Last resort: collect tilted data sets

Structure of the formoterol- β_1 AR- β arrestin1- F_{ab} 30 complex (Cryo-EM structure with an overall resolution of 3.3 Å)




Key aspects to structure determination

- Thermostabilised receptor (5 mutations)
- Sortase-mediated ligation of phosphorylated C-terminus
- Use of conformation-specific F_{ab} bound to arrestin
- Reconstitution of β_1 AR into a lipid nanodisc (POPC/POPG)
- Collection of data from 30° tilted samples




β -arrestin 1 finger loop



Formoterol

Preparation of β_1 AR-arrestin complex in nanodiscs





Conclusions

Cryo-EM is the method of choice for determining membrane protein structures

- Less biochemical intervention required
- Mild detergents and nanodiscs can be used
- Improvements in instrumentation & software ongoing
- Small membrane proteins can be stabilised by F_{ab}s or Nbs

Ste2 receptor dimer coupled to
two heterotrimeric G proteins
Nature (2021) 589, 148




Wild type receptor

- No deletions
- No mutations
- Post-translational modifications present

Keys to success

- Optimisation of every single step from cDNA to structure
- Ask 'Is ALL my protein functional?' at every step
- Being absolutely meticulous...
-and never, ever give up!



Present

Patricia Edwards
Lukas Helfinger
Yang Lee
Anastasia Gusach
Tony Warne
Vaithish Velazhahan

Past

Saba Abdul Hussein
Juni Andréll
Byron Carpenter
Javier García-Nafria
Vladimir Korkhov
Guillaume Lebon
Jennifer Miller-Gallacher
Rony Nehme
Tomomi Sato
Maria Serrano-Vega
Yoko Shibata
Ankita Singhal
Annette Strege
Jennifer Thomas
David Wright

GPCR Acknowledgements (2005-present)

LMB, UK

Richard Henderson
Andrew Leslie
Gebhard Schertler
Xiaochen Bai
Rouslan Moukahemtianov

Sosei Heptares, UK

Kirstie Bennett
Giles Brown
Miles Congreve
Chris de Graaf
Andy Doré
Ali Jazayeri
Nathan Robertson
Nigel Swain

University of
Nottingham, UK

Jillian Baker

City of Hope, Duarte

Nagarajan Vaidehi
Supriyo Bhattacharya
Sangbae Lee
Ning Ma

NIH, USA

Reinhard Grisshammer

University of Copenhagen,
Denmark

David Gloriam
Albert Kooistra
Gaspar Pandy-Szekeres

Indian Institute of Technology, Kanpur,
India

Arun Shukla
Shubhi Pandey
Hemlata Dwivedi-Agnihotri
Madhu Chaturvedi



MRC Laboratory
of Molecular
Biology

